This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Controlled Clinical Trial

FRANK W. MOUNT, MD

Arch Neurol. 1964;11(2):114-124.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Although it has been more than 20 years since Moehlig first used adrenal cortical extracts in the treatment of a patient with myasthenia gravis and reported "dramatic improvement"¹ the usefulness of corticotropin (ACTH) and corticosteroids in the treatment of this disease remained unsettled. Osserman² described them as "drugs to be used with extreme caution," and Schwab³ considered them "still of questionable value."

Why is there not a clearer understanding of the efficacy of these agents? This is partly because of the vagaries of the disease, ranging from apparently spontaneous remissions to sometimes equally sudden relapses. It is partly because of enthusiasms, the enthusiasm of the patient with his fervor to respond to a new treatment and the enthusiasm of the physician with his eagerness to help his patient. And partly, emphasized by the vagaries and the enthusiasms, it is because of inadequate trials. Perusal of the published . . . [Full Text PDF of this Article]

Author Affiliations
WASHINGTON, DC

Footnotes
Submitted for publication Feb 24, 1964; accepted March 24.

Special Projects Branch, National Institute of Neurological Diseases and Blindness.

This trial was supported in each hospital by a contract with the National Institute of Neurological Diseases and Blindness, Bethesda, MD.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?